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Protocol
AbstrACt
Introduction Endometrial trauma commonly known as 
endometrial scratch (ES) has been shown to improve 
pregnancy rates in women with a history of repeated 
implantation failure undergoing in vitro fertilisation (IVF), 
with or without intracytoplasmic sperm injection (ICSI). 
However, the procedure has not yet been fully explored in 
women having IVF/ICSI for the first time. This study aims 
to examine the effect of performing an ES in the mid-luteal 
phase prior to a first-time IVF/ICSI cycle on the chances 
of achieving a clinical pregnancy and live birth. If ES can 
influence this success rate, there would be a significant 
cost saving to the National Health Service through 
decreasing the number of IVF/ICSI cycles necessary to 
achieve a pregnancy, increase the practice of single 
embryo transfer and consequently have a large impact on 
risks and costs associated with multiple pregnancies.
Methods and analysis This 30-month, UK, multicentre, 
parallel group, randomised controlled trial includes a 
9-month internal pilot and health economic analysis 
recruiting 1044 women from 16 fertility units. It will follow 
up participants to identify if IVF/ICSI has been successful 
and live birth has occurred up to 6 weeks post partum. 
Primary analysis will be on an intention-to-treat basis. 
A substudy of endometrial samples obtained during the 
ES will assess the role of immune factors in embryo 
implantation. Main trial recruitment commenced on 
January 2017 and is ongoing. Participants randomised 
to the intervention group will receive the ES procedure in 
the mid-luteal phase of the preceding cycle prior to first-
time IVF/ICSI treatment versus usual IVF/ICSI treatment 
in the control group, with 1:1 randomisation. The primary 
outcome is live birth rate after completed 24 weeks 
gestation.
Ethics and dissemination South Central—Berkshire 
Research Ethics Committee approved the protocol. 
Findings will be submitted to peer-reviewed journals 
and abstracts to relevant national and international 
conferences.
trial registration number ISRCTN23800982; Pre-results.
bACkground
The use of local endometrial trauma known as 
endometrial scratch (ES) to improve implan-
tation rates in women undergoing assisted 
conception was first described in 2003.1 The 
procedure has since been explored in several 
studies mainly focusing on women with 
recurrent implantation failure and has been 
shown to significantly increase pregnancy 
rates by almost double.2–4 However, uncer-
tainty remains as to the therapeutic effect of 
ES, due to heterogeneity of the populations 
included—and the timing and exact protocol 
of ES used—in previous evaluations.5 6 Three 
systematic reviews have summarised the 
evidence, however, each included different 
studies.2 7 8 A recent Cochrane review 
included 14 randomised studies: 7 in women 
with previous cycle failure, 5 in an unselected 
population and 1 in a first-time cycle.8 The 
live birth rate (LBR) meta-analysis combined 
strengths and limitations of this study
 ► This is the largest multicentre, pragmatic ran-
domised controlled trial to date which aims to as-
sess the effectiveness and cost-effectiveness of 
performing the endometrial scratch (ES) procedure 
in women having in vitro fertilisation (IVF)/intracyto-
plasmic sperm injection (ICSI) for the first time.
 ► It aims to determine whether performing an ES is an 
acceptable and well-tolerated procedure.
 ► Due to the nature of the intervention, it is not possi-
ble to blind study participants or clinicians.
 ► Potential difficulty with recruitment if patients are 
not in equipoise about effectiveness of the ES pro-
cedure in first-time IVF/ICSI cycles.
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trials regardless of the population (ie, number of 
previous in vitro fertilisation (IVF) cycles) and included 
five studies, reporting a risk ratio (RR) of 1.42 (95% CI 
1.08 to 1.85), p=0.02. The odds of achieving a clinical 
pregnancy were also increased following ES with an RR 
of 1.34 (95% CI 1.11 to 1.62), p=0.002. The one trial 
conducted in women undergoing their first IVF cycle 
indicated the procedure was harmful with an OR of 
clinical pregnancy rate of 0.30 (95% CI 0.14 to 0.63), 
p=0.002.9 Notably, this trial performed the ES proce-
dure at the time of oocyte retrieval and not in the month 
prior to the IVF cycle. Despite the concerns around the 
quality of evidence in using ES and that many of the trials 
undertaken so far have been small (most <150 partici-
pants), ES has been widely adopted into routine clinical 
practice in women with recurrent unsuccessful implan-
tation and is currently being provided in some fertility 
units where women are having IVF/intracytoplasmic 
sperm injection (ICSI) for the first time.10 11 Two large 
trials are currently in progress to determine if ES is bene-
ficial in women undergoing their second IVF cycle12 and 
a sample of women undergoing any IVF cycle.13 There-
fore, given the lack of evidence for the effectiveness of 
ES in women undergoing their first cycle of IVF/ICSI, it 
is essential that a large well-controlled multicentre trial is 
conducted to fully investigate the effectiveness and safety 
of this technique.
The Human Fertilisation and Embryology Authority 
(HFEA) state in their statistical report into multiple 
births that the risks associated with multiple births is the 
single biggest health risk associated with fertility treat-
ment.14 Multiple births carry risks to the health of both 
the mother and the babies and that birth of a healthy 
singleton child, born at full term, is therefore the safest 
outcome of fertility treatment for both mother and child 
and is best achieved through promoting the practice of 
single embryo transfer (SET).
If ES can improve the implantation potential of the 
embryo and therefore improve success rates, ES may 
encourage an expansion of current SET policies. Inclu-
sion of women with a lower chance of having cryopre-
served embryos and a more general increase in the 
implementation of the practice of SET, could conse-
quently have a large impact on the risks and costs associ-
ated with multiple pregnancies as a result of IVF.15
The exact mechanism by which ES may improve 
implantation is not yet known, however, it is known that 
implantation is a complex process involving a number of 
inflammatory mediators including uterine natural killer 
cells, leukaemia inhibitory factor and interleukin 15.13 It 
is possible that ES may lead to the activation of inflam-
matory cells such as macrophages and dendritic cells, 
and release of inflammatory mediators such as tumour 
necrosis factor-α, interleukin-15, growth-regulated onco-
gene-α and macrophage inflammatory protein 1B.14
ES has also been shown to cause the modulation 
of several endometrial genes that may be involved in 
membrane stability during the process of implantation 
such as bladder transmembranal protein (UPIb) and 
adipose differentiation-related protein and mucin 1.16
ES is routinely performed as an outpatient procedure. 
Risks have been identified in a previous study when the 
procedure was undertaken on the day of oocyte retrieval 
(reduced implantation and pregnancy rates)9; however, 
the procedure is not known to be associated with any 
particular risks when undertaken in the menstrual cycle 
preceding that of IVF therapy, apart from period like 
discomfort while performing the procedure. Taking 
simple analgesics prior to the procedure usually alleviates 
this. As with any intrauterine procedure, there is a poten-
tial for intrauterine infection. However, women attending 
for fertility treatment are usually screened for serious 
vaginal infections such as chlamydia to minimise the risk 
of any spread of infection when performing the embryo 
transfer procedure, a similar procedure to an ES as it 
involves the insertion of a catheter into the uterine cavity.
The main objectives of this trial are to assess the clinical 
and cost-effectiveness of the ES procedure in women aged 
between 18 and 37 years (inclusive) undergoing their first 
IVF/ICSI cycle using either antagonist or long protocols 
to see if it could potentially improve implantation rates 
and hence encourage the practice of single embryo 
replacement. A substudy will be undertaken in two of the 
fertility units where endometrial samples obtained from 
the ES procedure will be stored for later analysis to iden-
tify endometrial factors associated with successful preg-
nancy outcome.
MEthod And AnAlysIs
The ES trial is a multicentre, parallel group, randomised 
controlled trial to examine the clinical, cost-effectiveness 
and safety of an ES performed in the mid-luteal phase 
of the preceding cycle prior to a first-time IVF/ICSI 
cycle. Eligible participants will be randomised to either 
the treatment-as-usual (TAU) arm, consisting of usual 
IVF treatment, or the intervention arm where ES will be 
performed followed by usual IVF treatment. The overall 
study design is illustrated below in the study flow chart 
(figure 1).
Patient and public involvement
The study was reviewed by couples waiting to commence 
IVF treatment and then by the members of The Jessop 
Wing Reproductive Health Public Advisory Panel, 
(patient and public involvement (PPI)) at the Jessop 
Wing, Sheffield. All were asked to provide input into 
the lay summary, recruitment strategy, visit schedule and 
benefits of the proposed study to the patient and the 
National Health Service (NHS). We asked about their 
experience of assisted conception, the things they liked 
and disliked, and the potential difficulties or barriers 
to attending for treatment, randomisation to the TAU 
arm and how this might affect recruitment but clarified 
that if the trial showed an increase in the scratch arm 
assisting embryo implantation, then it would form part 
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of the routine care pathway in the future. A member of 
the panel agreed to become the service user representa-
tive, is a member of the steering committee and attended 
the trial investigator/set-up meeting providing a patients 
view of all aspects associated with IVF. All PPI members 
have provided input into the patient facing documents 
on an ongoing basis and prior to submission to ethics and 
are aware of recruitment and the conduct of the study at 
ongoing PPI events held on a bimonthly basis within the 
directorate.
The most significant changes to the health technology 
assessment (HTA) grant influenced by the PPI members 
were in relation to trial follow-up procedures as they 
felt only women who achieved a pregnancy should be 
followed up. They also wanted to ensure continuity across 
the participating centres when performing the follow-up 
visits and requested a proforma be designed to ensure all 
research nurses/midwives capture the same information.
On completion of the trial, the results will be summarised 
in plain English and distributed to participants and 
patient support groups such as Infertility Network UK 
with the assistance of our service-user collaborators. We 
will promote the transfer of knowledge to wider audi-
ences including the general public (eg, including short, 
user-friendly articles/briefings in relevant newsletters, 
magazines and periodicals, user groups/forums).
Figure 1 Study flow chart. AEs, adverse events; ES, endometrial scratch; ICSI, intracytoplasmic sperm injection; IVF, in vitro 
fertilisation; RN, Research Nurse.
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Trial Design
The trial consists of two phases—an internal pilot to assess 
feasibility of recruitment and delivery of the intervention, 
and a 2-year main recruitment phase.
The trial will commence with a 9-month internal pilot 
recruitment phase across approximately six UK fertility 
units to justify whether or not the recruitment strategy 
and the scheduling of the ES procedure are feasible and 
will use the same trial procedures as described for the 
main trial.
The trial is collaboration between research staff at The 
Jessop Wing, Sheffield Teaching Hospital NHS Foun-
dation Trust and The University of Sheffield—Clinical 
Trials Research Unit (CTRU) who is responsible for the 
conduct of the trial. Funding to run the trial has been 
awarded by the National Institute for Healthy Research 
HTA. At the end of the pilot phase, the trial steering 
committee (TSC) will report to the funder on whether 
the feasibility criteria have been met and whether the 
trial should continue.
The trial will be conducted in compliance with the 
approved protocol, Good Clinical Practice and regula-
tory requirements. Main trial recruitment commenced 
on January 2017 and is ongoing.
Sheffield CTRU will aggregate feasibility of the research 
and intervention protocols. The trial will be considered 
infeasible and will be stopped if either of the following 
conditions apply:
1. Feasibility of recruitment to the main trial: defined as 
recruitment of fewer than 108 participants (75% of 
the 144 target) during the internal pilot phase.
2. Scheduling of the ES procedure: defined as less than 
75% of women scheduled to receive their ES proce-
dure have received the ES at the correct time point.
Recruitment
On successful completion of the pilot the main trial will 
aim to recruit women from 16 UK fertility units requiring 
first-time IVF treatment. Participation is entirely volun-
tary and choosing not to participate will not negatively 
influence the woman’s treatment in any way. Further-
more consent can be withdrawn at any stage. Women who 
are about to undergo their first cycle of IVF/ICSI will be 
identified by screening patients referred for these treat-
ments. Eligible women will be sent information regarding 
the trial in the post or via email or may be alerted to the 
trial via the trial website or posters displayed at the fertility 
unit. If they are interested in participating, they will be 
invited to discuss the trial with their fertility team at their 
next routine appointment.
Prior to randomisation full written informed consent 
will be obtained by a suitably trained doctor or research 
nurse/midwife at a clinic visit. The participant will 
complete a study-specific resource use questionnaire 
prior to randomisation to collect healthcare usage in the 
previous 3 months; baseline data will be collected at this 
visit and participants will be randomly allocated to either 
the intervention or usual care arm of the trial.
Detailed methods of the ES trial are described in the ES 
protocol available on the website (https://www. sheffield. 
ac. uk/ scratchtrial).
Women will be included and considered suitable if they 
meet the following eligibility criteria:
Inclusion criteria
1. Women expected to be aged between 18 and 37 years 
(inclusive) at time of egg collection.
2. First-time IVF with or without ICSI treatment using 
the antagonist or long protocol only.
3. Expected to receive treatment using fresh embryos.
4. Expected good responders to treatment, with:
a. Ovulatory menstrual cycle (Regular menstrual 
cycles defined by clinical judgement or with ovu-
latory levels of mid-luteal serum progesterone as 
defined by local laboratory protocols).
b. Normal uterine cavity (assessed by transvaginal so-
nography at screening and no endometrial abnor-
malities such as, suspected intrauterine adhesions, 
uterine septa, submucosal fibroids or intramural 
fibroids exceeding 4 cm in diameter as assessed by 
the investigator that would require treatment to 
facilitate pregnancy).
c. Expected good ovarian reserve (assessed clinical-
ly, biochemically (follicle-stimulating hormone 
(FSH) <10 and normal follicular phase oestradi-
ol levels and or normal anti-mullerian hormone 
(AMH)), and or sonographically (antral follicle 
counts) and no history of previous radiotherapy or 
chemotherapy). (All laboratory/ultrasound stan-
dards based on local normal reference ranges.)
d. SET expected.
5. Local procedures have been/will be followed to ex-
clude relevant vaginal/uterine infections prior to 
starting treatment.
6. Willing to use an appropriate method of barrier con-
traception if randomised to ES in the cycle where the 
ES procedure is performed.
7. Understands/willing to comply with the protocol.
Exclusion criteria
1. Previous trauma/surgery to the endometrium (eg, re-
section of submucous fibroid, intrauterine adhesions).
2. Body mass index (BMI) of 35 kg/m2 or greater.
3. Known grade 4 (severe) endometriosis.
4. Currently participating in any other fertility study in-
volving medical/surgical intervention.
5. Expected to receive protocols other than antagonist 
or long (eg, ultralong protocol).
6. An ES (or similar procedure, eg, endometrial biopsy 
for the collection of natural killer cells) is planned.
7. Previously randomised into this trial.
Sampling
The primary outcome is the LBR. This is defined as a 
live birth after completed 24 weeks gestation, within the 
10.5-month post-egg collection follow-up period. This 
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time period will enable the collection of any neonatal 
deaths (up to 6 weeks post partum). The denominator 
for calculating the LBR will be the number of women 
randomised to each group. Data from the HFEA suggest 
an LBR of 32.8% in women under 35% and 27.3% in 
women aged 35–37. The sample size calculation assumes 
a 30% LBR in the control group and that an absolute 
increase of 10%, to a 40% LBR (a relative risk of 1.33) in 
the intervention groups is of clinical and practical impor-
tance. The effect size, a 10% absolute difference in LBR, 
we are proposing is large, but we believe an effect of such 
magnitude is needed to change clinical practice (there 
is a 5% absolute difference in LBR between women aged 
under 35 and 35–37) and is less than that observed in the 
systematic reviews described above (where, at the time of 
sample size calculation, the relative risk estimates for live 
birth ranged from 1.83 to 2.46).2 17 To have a 90% power 
of detecting this difference or more, in LBR rates between 
the groups, as statistically significant at the 5% two-sided 
level, will require 496 women per group (992 in total). 
Adjusting for a predicted drop-out rate of 5% (due to 
anticipated difficulties of follow-up for patients who have 
been referred from NHS Trusts other than the partici-
pating fertility unit), we will require 1044 participants.
Study procedures
Following randomisation women in the intervention arm 
will have the ES procedure performed in the mid-luteal 
phase of the preceding cycle prior to their planned IVF/
ICSI cycle in the outpatient setting of the fertility unit. The 
choice of screening for infection prior to the procedure or 
the administration of antibiotics will be left to individual 
units according to their local established protocols and 
procedures. Women can be randomised any time up until 
they start their IVF cycle, although it may be necessary 
for the participant to delay her IVF if randomised to the 
intervention arm. This decision to delay should be made 
and agreed by both the patient and her fertility team 
before randomisation is undertaken. The contraceptive 
pill/oral contraceptives can be used following randomis-
ation for the purposes of cycle programming, but women 
must be having ovulatory periods at the point of entry 
into the trial. Women randomised to TAU will continue 
with their IVF/ICSI as planned and will not receive the 
ES procedure.
Following delivery of the ES, participants will undergo 
IVF/ICSI in line with local procedures. Following 
successful embryo transfer (in both groups), a pregnancy 
test will be performed and adverse events (AEs) will be 
collected. In cases where women do not undergo embryo 
transfer, every effort will be made by the research team to 
collect any AE information from either the patient or the 
medical notes. If a pregnancy is confirmed, the woman 
is discharged to normal antenatal care as per standard 
practice. It is the intention to obtain the pregnancy status 
of all women once randomised including the outcome 
of all spontaneous pregnancies, the first frozen embryo 
transfer if no fresh transfer has been undertaken as well 
as those that delay treatment following the ES. Women 
will not be followed up if they withdraw their consent 
from the trial. Data will also be collected regarding partic-
ipants who have received an ES outside the trial.
Randomisation
The randomisation schedule will be generated by Shef-
field CTRU prior to the start of the trial; access to the 
schedule will be limited only to the trial statistician. The 
randomisation sequence will be computer generated 
and stratified by site and protocol (antagonist or long 
protocol). Random permuted blocks of variable size 
will be used to ensure enough participants are allocated 
evenly to each arm of the trial at each site. Research staff 
at recruiting centres will be unable to access the rando-
misation sequence and will use a web-based computer 
system with restricted access rights to enter participant 
details; randomisation outcome will then be revealed. 
Re-randomisation will not be permitted.
Trial intervention
ES is a minor procedure of 10–20 min duration that will be 
performed in an outpatient setting at local IVF centres in 
line with local procedures and the trial standard operation 
procedure (SOP). The participant will be required to use 
a barrier method of contraception (if necessary) during 
the menstrual cycle in which the ES will be performed. 
During ES, a speculum is inserted into the vagina and the 
cervix exposed and cleaned. A pipelle or similar endome-
trial sampler is then inserted into the cavity of the uterus; 
negative pressure is applied by withdrawal of the plunger. 
The sampler is rotated and withdrawn several times so 
that tissue appears in the transparent tube. The sampler 
and speculum are then removed. If no tissue is seen in the 
transparent sampler, this is an indication that the sampler 
was not fully inside the uterine cavity and therefore the 
procedure is repeated. Following the procedure, women 
will complete a Visual Pain Scale (Likert) to assess their 
pain and tolerability assessment of the procedure within 
30 min of the initial ES and then again at 24 hours and 7 
days postprocedure via an automated text message.
Compliance to the intervention will be ascertained 
through the clinician or research nurse/midwife 
recording whether or not the patient has (1) attended 
the clinic for the ES procedure and (2) received the ES 
procedure as per protocol (PP). Any deviation from the 
protocol will be noted and reported as per the Sheffield 
CTRU SOP.
Follow-up
Patient follow-up will continue until either the first cycle 
of IVF has been completed or the resulting pregnancy 
has concluded. If no pregnancy is confirmed, the study 
is complete (regardless of which group the woman is 
randomised to). Pregnant women will be followed up 
at 3 and 6 months post-egg collection and then 6 weeks 
post partum to collect pregnancy outcome and safety 
data. If the pregnancy is ongoing at 3 months and 6 weeks 
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post partum, a health resource use questionnaire will 
be sent to the patient for completion. If a spontaneous 
pregnancy is achieved between randomisation and IVF 
treatment, the pregnancy will be followed up as described 
above, instead of egg collection, the date of the last 
menstrual period will be used to schedule the 3/6 months 
and 6 weeks postpartum follow-ups.
Safety considerations, safety monitoring and AE reporting
All AEs and serious AEs (SAEs) will be recorded by the 
local research team at each fertility unit. All AEs/SAEs 
will be followed up until satisfactory resolution or until 
the treating clinician and the principal investigator (PI) 
deems the event to be chronic or the participant to be 
stable. Research nurses/midwives will ask patients for 
any details of AEs at five time points: post procedure 
(if randomised to receive ES), at the participants’ preg-
nancy test, and then, if pregnancy has been achieved, at 
3 and 6 months post-egg collection and finally 6 weeks 
post partum.
AEs/SAEs will be collected up to the participants’ 
final study-related follow-up event. If embryo transfer 
does not occur, the research nurse/midwife will contact 
the participant approximately 2 weeks after egg collec-
tion to identify if any AEs have occurred. In the case of 
a negative pregnancy test, the site research team should 
make every effort to obtain AE data from the patient or 
the medical notes at routine clinical care contacts; no 
further contact will be made outside of routine clinical 
care.
Expected AEs will be those which occur regularly due 
to pregnancy, and expected SAEs are those events which 
are expected in the patient population as a result of the 
routine care/treatment of a patient. Expected SAEs and 
all AEs will be collected as part of the trial and entered 
into the electronic case report form, but will not be 
reported to regulatory bodies (NHS REC/sponsor).
Unexpected SAEs will be reported to the Sheffield 
CTRU as soon as staff at the fertility units become aware 
of the event.
All SAEs will be reviewed by the data monitoring and 
ethics committee (DMEC) and trial management group 
(TMG) at regular intervals. The chief investigator will 
inform all PIs concerned of relevant information that 
would adversely affect the safety of the participants.
Outcomes
Primary clinical outcome
 ► Live birth rate based on the number of live births after 
24 weeks gestation within the 10.5-month post-egg 
collection follow-up period.
Secondary outcomes
 ► Acceptability and pain rating of the ES procedure, 
a Visual Pain Scale (Likert) to assess their pain and 
tolerability assessment of the procedure within 30 min 
of the initial ES procedure, 1 day later and then again 
7 days after the ES.
 ► Implantation rate based on a positive serum 
beta human chorionic gonadotropin (hCG) on 
approximately day 14 following the egg collection or 
by a positive urine pregnancy test.
 ► Clinical pregnancy rate: an observation of viable intra-
uterine pregnancy with a positive heart pulsation seen 
on ultrasound at/after 8 weeks gestation.
 ► Miscarriage rate as measured by spontaneous preg-
nancy loss (including pregnancy of unknown location 
prior to 24 weeks gestation within the 10.5-month 
post-egg collection follow-up period.
 ► Ectopic pregnancy as measured by the rate of preg-
nancy outside the normal uterine cavity.
 ► Multiple birth rate defined as the birth of more than 
one living fetus after completed 24 weeks gestation.
 ► Preterm delivery rate as measured by live birth after 
24 weeks but before 37 weeks gestation within the 
10.5-month postegg collection follow-up period.
 ► Stillbirth rate based on the delivery of a stillborn fetus 
showing no signs of life after 24 weeks gestation within 
the 10.5-month post-egg collection follow-up period.
 ► Details of participant’s IVF cycles including number 
of eggs retrieved, number of embryos generated 1 day 
after egg collection, quality of the embryos transferred 
(using National External Quality Assessment Service 
(NEQAS) grading) and the number of embryos 
replaced and day of embryo replacement.
 ► AEs.
 ► Health resource use of the participant and patient 
costs.
The trial includes a health economic component to 
assess the cost of the intervention per extra live birth 
from an NHS and social care perspective. Resource use 
will include the intervention costs for ES, the cost of IVF 
treatment, visits to the Assisted Conception Unit and 
for those who conceive antenatal and postnatal visits, 
delivery costs and any hospital stays not related to birth 
for both mother and baby. The resource use question-
naire will collect information on contacts with midwife 
and general practitioner visits. A Patient Cost question-
naire will collect time taken to travel to appointments and 
loss of productivity. Unit costs will be derived from appro-
priate national sources and will include; NHS reference 
costs, Personal Social Service Research Unit costs and the 
Office of National Statistics.18–20 The resource use ques-
tionnaire will be designed for this study and will draw on 
data collection tools developed in The School of Health 
and Related Research and those collated by the Database 
of Instruments for Resource Use Measurement.
Blinding
Since this trial evaluates objectively measured outcomes 
(pregnancy rates) that are unlikely to be affected by a 
placebo effect, participants will not be blinded to treat-
ment allocation; it is therefore not necessary to perform 
a sham procedure for the control group. The study stat-
istician, TSC and health economist will be blinded to the 
allocation.
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trial monitoring and oversight committees
The trial will be overseen by the TSC and the DMEC, 
membership of both will consist of independent experts 
in the field. The TSC will include a patient represen-
tative. Both committees will review recruitment, study 
progress and AEs. The DMEC will receive monthly 
reports of recruitment and AEs and, at their meetings, 
will also consider emerging evidence from other trials 
or research on ES. They may advise the chair of the TSC 
at any time if, in their view, the trial should be stopped 
for ethical reasons, including concerns about patient 
safety.
Day-to-day running of the trial will be coordinated 
by the TMG, consisting of the grant coapplicants, plus 
members of the Jessop Wing Fertility Unit, Sheffield 
CTRU and Patient representatives.
statistical analysis
Primary analysis will be performed on the intention-to-
treat population (all participants randomised into the 
trial). All statistical exploratory tests will be two tailed at 
5% nominal level. Baseline demographic (eg, age), phys-
ical measurements (eg, BMI) and health-related data 
will be described and summarised overall and for both 
treatment groups. The women, not the IVF cycle, will be 
the unit of analysis. If the woman fails to get pregnant or 
does not have IVF treatment, they will be included in the 
analysis of the primary outcome as a negative outcome 
(ie, non-live birth). For sensitivity analyses, PP analyses 
will also be undertaken which will be defined as for ES 
participants in the intervention group, receiving the ES 
procedure as documented in the study protocol and 
undergoing IVF/ICSI in the subsequent menstrual cycle, 
including embryo transfer. For the control group, the 
PP population will receive IVF/ICSI including embryo 
transfer. Subgroup analyses will be undertaken to explore 
the effect of important variables related to the partici-
pant and their treatment on the primary and secondary 
outcomes. These subgroups are:
 ► Day of embryo transfer (day 2, 3, 4, 5 or 6).
 ► Fertilisation method (IVF, IVF or ICSI, ICSI (spilt)).
 ► Type of protocol (long or antagonistic).
 ► Embryo transfer (single or double) and whether the 
embryo was fresh or frozen.
 ► Previous history of consecutive miscarriages (0–2 vs 
≥3).
AEs will be reported as a proportion of all women 
randomised. AEs including SAEs will be compared 
between the two groups using a Fisher’s exact test, χ2 
test or negative binomial regression model in case of 
repeated events per woman (as appropriate). A 95% CI 
for the difference in AE rate between the groups will also 
be calculated with associated point estimate depending 
on the method used.
Health economic results will be presented in the 
net-benefit framework and will allow for uncertainty 
using bootstrapping and probabilistic sensitivity analysis.
Ethics and dissemination
The findings of this trial will be submitted to peer-re-
viewed journals and abstracts to national and interna-
tional conferences. Other stakeholder-specific outputs in 
relevant formats will also be produced for commissioners, 
IVF practitioners, third sector and user advocacy organ-
isations. A website will be established to promote the 
work of the trial. All knowledge transfer activity including 
translation will be informed by input from trial collabora-
tors, the TSC and TMG to ensure the study is meeting the 
needs of the commissioners and audience.
dIsCussIon
This trial will determine whether performing an ES proce-
dure prior to first-time IVF/ICSI treatment is an inex-
pensive, safe and well-tolerated procedure that increases 
the LBR in women having SET. If shown to be the case, 
this will have a significant improvement in first cycle 
IVF success rates and potentially lead to significant cost 
savings to the NHS as fewer women would need to have 
repeat treatment cycles. This is particularly important in 
the current economic climate and with restrictions on 
funding and service provision. This will also have a signifi-
cant impact for women, for whom the burden of repeated 
cycles is large.
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